Cellular senescence in naevi and immortalisation in melanoma: a role for p16?
Gray-Schopfer VC, Cheong SC, Chong H, Chow J, Moss T, Abdel-Malek ZA, Marais R, Wynford-Thomas D, Bennett DC. · 2006
Read Cellular senescence in naevi and immortalisation in melanoma: a role for p16? by Gray-Schopfer VC, Cheong SC, Chong H, Chow J, Moss T, Abdel-Malek ZA, Marais R, Wynford-Thomas D, Bennett DC. (2006) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2360676.txt.
Introduction
Gray-Schopfer and co-authors examined how moles avoid becoming melanoma in 2006. Melanoma is a deadly skin cancer, and moles are its common starting point. Cells can enter senescence, a permanent stop to division, and the authors asked whether this stop acts as a barrier in real tissue.
In lab-grown human pigment cells, switching off a protein called p16 was required, alongside telomerase, for cells to divide forever. Staining of real moles showed wide p16 presence and signs of senescence, without rises in two other markers, p53 and p21. Early melanomas had less p16, while advanced melanomas lacked both p16 and p21 in most areas. A faulty growth gene, BRAF, found in about 80% of moles, switched p16 on. The authors concluded senescence blocks melanoma, which explains why p16 loss promotes it.
Catalog record
| CREATOR | Gray-Schopfer VC, Cheong SC, Chong H, Chow J, Moss T, Abdel-Malek ZA, Marais R, Wynford-Thomas D, Bennett DC. |
|---|---|
| YEAR | 2006 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Cellular senescence in naevi and immortalisation in melanoma: a role for p16? By V C Gray-Schopfer, S C Cheong, H Chong, J Chow, T Moss, Z A Abdel-Malek, R Marais, D Wynford-Thomas, D C Bennett Published in: British Journal of Cancer DOI: 10.1038/sj.bjc.6603283 ABSTRACT Cellular senescence, the irreversible proliferative arrest seen in somatic cells after a limited number of divisions, is considered a crucial barrier to cancer, but direct evidence for this in vivo was lacking until recently. The best-known form of human cell senescence is attributed to telomere shortening and a DNA-damage response through p53 and p21. There is also a more rapid form of senescence, dependent on the p16-retinoblastoma pathway. p16 (CDKN2A) is a known melanoma susceptibility gene. Here, we use retrovirally mediated gene transfer to confirm that the normal form of senescence in cultured human melanocytes involves p16, since disruption of the p16/retinoblastoma pathway is required as well as telomerase activation for immortalisation. Expression (immunostaining) patterns of senescence mediators and markers in melanocytic lesions provide strong evidence that cell senescence occurs in benign melanocytic naevi (moles) in vivo and does not involve p53 or p21 upregulation, although p16 is widely expressed. In comparison, dysplastic naevi and early (radial growth-phase, RGP) melanomas show less p16 and some p53 and p21 immunostaining. All RGP melanomas expressed p21, suggesting areas of p53-mediated senescence, while most areas of advanced (vertical growth-phase) melanomas lacked both p16 and p21, implying escape from both forms of senescence (immortalisation). Moreover, nuclear p16 but not p21 expression can be induced in human melanocytes by oncogenic BRAF, as found in around 80% of naevi. We conclude that cell senescence can form a barrier to melanoma development. This also provides a potential explanation of why p16 is a melanoma suppressor gene. Cellular senescence, the growth arrest seen in normal mammalian cells after a limited number of divisions, is controlled by key tumour suppressors including p53 and p16, and is believed to be a crucial barrier to tumour development (Sharpless and DePinho, 2004). However, evidence for this overall concept comes very largely from cell cultures and animal models (Wynford-Thomas, 1999; Sherr, 2001; Sharpless and DePinho, 2004). No direct evidence has yet been presented that cell senescence forms a true barrier to development of human cancers in vivo, although improved evidence from animal models has emerged recently (Braig et al, 2005; Collado et al, 2005). Two main pathways effecting normal cellular senescence in culture have been reported. The best known form of senescence, first described in fibroblasts, is effected primarily by the p53 pathway (Wynford-Thomas, 1999; Sherr, 2001; Sharpless and DePinho, 2004), and can be overcome by expression of exogenous hTERT (human telomerase reverse transcriptase, required for telomere maintenance), to give immortal (indefinitely proliferating) cultures (Bodnar et al, 1998). Here, senescence appears to be dependent on limited shortening of telomeres, activating p53 through checkpoint kinases 2 and possibly 1 (CHK2 and CHK1) (Stewart et al, 2003; d'Adda di Fagagna et al, 2003; Von Zglinicki et al, 2005). An alternative route to senescence was reported in certain epithelial cells. It involves only the p16/RB1 pathway, and the cells require interference with this pathway as well as hTERT expression, for immortalisation (Kiyono et al, 1998). p16-dependent senescence was abolished by disruption of the RB1 pathway, after which a further, p53-dependent growth arrest was observed. p16-dependent arrest of epithelial cells was, however, circumvented by culture with growth-inactivated fibroblast ‘feeder’ cells. The cells showed extended proliferation, p53-dependent senescence, and immortalisation with hTERT alone (Ramirez et al, 2001). The authors suggested that p16-dependent senescence was an artefact of imperfect culture conditions, leading to ‘stress’ (Ramirez et al, 2001). In p16-dependent senescence, the cyclin-dependent kinase (CDK) inhibitor p16 is synthesised and activates RB1, by inhibiting phosphorylation of RB1 by CDK4 or CDK6 (Kiyono et al, 1998; Sharpless and DePinho, 2004). p16 is itself a tumour suppressor; germline mutations at its locus CDKN2A are principally associated with familial melanoma in humans, with some increased incidence of pancreatic cancer, suggesting particular importance in melanocytes (Gruis et al, 1995; Bennett, 2003; Hayward, 2003; Kefford et al, 2004; Gray-Schopfer and Bennett, 2006). In sporadic cancers, p16 alterations and deletions are more broadly distributed, being found in many types of cancer. The COSMIC database of over 13 000 cancer samples (Forbes et al, 2006) (http://www.sanger.ac.uk/genetics/CGP/cosmic/) lists p16 point mutations in 15% of all tested samples, including nearly every cancer type tested, although the frequency varies with type and culture status (22% for melanoma, 9% for all uncultured melanoma samples). This does not include deletions, and a recent study by comparative genome hybridisation highlighted p16 as the most commonly deleted gene in uncultured primary melanomas, at 50% frequency (Curtin et al, 2005). Thus, at least 59% of uncultured melanomas apparently have a p16 deficiency. To this can be added gene silencing; CDKN2A promoter methylation was reported in 19% of invasive primary melanomas (Straume et al, 2002). Moreover, a study with melanoma cell lines found that 100% of lines with normal p16 had a different alteration in the RB pathway (Bartkova et al, 1996). It is not clear how many other cancer types show such high total frequencies of somatic p16 alteration; but even if the specific relation between p16 and melanoma is restricted to germline mutations, it is interesting that there is evidence for the p16-dependent form of senescence in human melanocytes, even in a rich culture medium and with feeder cells (Bennett and Medrano, 2002; Sviderskaya et al, 2003). Two human melanocyte strains lacking functional p16 both showed a greatly extended lifespan, p53-dependent senescence, and immortalisation by hTERT alone (Sviderskaya et al, 2003). These findings suggested a parallel with melanocytic lesions. Humans carrying p16 mutations have not only increased susceptibility to melanoma, but usually also numerous melanocytic naevi (moles), often large (Gruis et al, 1995; Bennett and Medrano, 2002; Bennett, 2003), implying a role for p16 in limiting naevus growth in these families. This led to surmises that moles may be melanocyte clones that have proliferated following a first mutation, then senesced (Bennett and Medrano, 2002; Mooi and Peeper, 2002; Bastian, 2003). Reports of activating BRAF mutations in most melanomas (Davies et al, 2002) and around 80% of naevi (Pollock et al, 2003) provided a likely candidate for the mutation that most commonly initiates proliferation. BRAF is a protein serine/threonine kinase that transduces mitogenic and other signals from RAS to MAPK (Robinson and Cobb, 1997) and can regulate cell proliferation. The most common oncogenic BRAF mutation in melanomas, V600E (formerly called V599E), results in constitutive ERK signalling in vivo and can transform immortal fibroblasts (Davies et al, 2002) and immortal mouse melanocytes (Wellbrock et al, 2004). The senescence studies also suggested mechanisms for progression to melanoma. Malignant melanomas can originate in naevi, sometimes through intermediate lesions (Clark et al, 1984; Herlyn et al, 1985; Mooi, 1997; Hussein and Wood, 2002), as follows. Dysplastic naevi tend to be large, with architectural irregularities but not progressive growth, unlike melanoma (Mooi, 1997). Radial growth phase (RGP) melanomas are thin, growing only in or near the epidermis, while vertical growth phase (VGP) melanomas invade more deeply and are competent for metastasis and immortal in cell culture (Clark et al, 1984; Herlyn et al, 1985; Clark,